These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16995421)

  • 21. A perforin/granzyme-positive MDS-derived T cell line, K2-MDS, induces apoptosis in CD34+ cells through the fractalkine-CX3CR1 system.
    Morita Y; Matsuda M; Hanamoto H; Shimada T; Tatsumi Y; Maeda Y; Kanamaru A
    Clin Immunol; 2004 Oct; 113(1):109-16. PubMed ID: 15380536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nucleolar abnormalities--a defect of the nucleolar preribosome assembly--in ringed sideroblasts in refractory anaemia with ringed sideroblasts (RARS) of myelodysplastic syndrome (MDS). An electron microscopic study.
    Smetana K; Cermák J; Jirásková I; Malasková V
    Sb Lek; 2003; 104(2):199-207. PubMed ID: 14577129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Maturation-associated immunophenotypic abnormalities in bone marrow B-lymphocytes in myelodysplastic syndromes.
    Ribeiro E; Matarraz Sudón S; de Santiago M; Lima CS; Metze K; Giralt M; Saad ST; de Matos AO; Lorand-Metze I
    Leuk Res; 2006 Jan; 30(1):9-16. PubMed ID: 16005514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Study on the burden of abnormal hematopoietic clone of the patients with myelodysplastic syndromes and its implications].
    Wang HQ; Shao ZH; Shi J; Cao YR; Liu H; Bai J; Tu MF; Xing LM; Cui ZZ; Liu SH; Sun J; Jia HR; Yang TY
    Zhonghua Xue Ye Xue Za Zhi; 2005 Aug; 26(8):473-6. PubMed ID: 16383238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Mixed myelodysplastic and myeloproliferative syndromes].
    Neuwirtová R; Mociková K; Jelínek J; Musilová J; Havlícek F; Adamkov M; Michalová K; Cermák J; Jonásová A; Smolíková A; Straub J; Tothová E; Voglová J; Vozobulová V; Waltrová L
    Cas Lek Cesk; 1997 Dec; 136(23):724-9. PubMed ID: 9476375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Classification and scoring systems in myelodysplastic syndromes: a retrospective analysis of 311 patients.
    Navarro I; Ruiz MA; Cabello A; Collado R; Ferrer R; Hueso J; Martinez J; Miguel A; Orero MT; Pérez P; Nolasco A; Carbonell F
    Leuk Res; 2006 Aug; 30(8):971-7. PubMed ID: 16423393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA instability in low-risk myelodysplastic syndromes: refractory anemia with or without ring sideroblasts.
    Novotna B; Neuwirtova R; Siskova M; Bagryantseva Y
    Hum Mol Genet; 2008 Jul; 17(14):2144-9. PubMed ID: 18430715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia.
    Blau O; Hofmann WK; Baldus CD; Thiel G; Serbent V; Schümann E; Thiel E; Blau IW
    Exp Hematol; 2007 Feb; 35(2):221-9. PubMed ID: 17258071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts.
    Nearman ZP; Szpurka H; Serio B; Warshawksy I; Theil K; Lichtin A; Sekeres MA; Maciejewski JP
    Am J Hematol; 2007 Dec; 82(12):1076-9. PubMed ID: 17654685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of CD55- and CD59-deficient granulocytic populations in patients with myelodysplastic syndrome.
    Kaiafa G; Papadopoulos A; Ntaios G; Saouli Z; Savopoulos C; Tsesmeli N; Kontoninas Z; Chatzinikolaou A; Tsavdaridou V; Klonizakis I; Hatzitolios A
    Ann Hematol; 2008 Apr; 87(4):257-62. PubMed ID: 18158579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations.
    Tehranchi R; Fadeel B; Schmidt-Mende J; Forsblom AM; Emanuelsson E; Jadersten M; Christensson B; Hast R; Howe RB; Samuelsson J; Zhivotovsky B; Hellström-Lindberg E
    Clin Cancer Res; 2005 Sep; 11(17):6291-9. PubMed ID: 16144933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of myelodysplastic syndrome and aplastic anemia by immunostaining of p53 and hemoglobin F and karyotype analysis: differential diagnosis between refractory anemia and aplastic anemia.
    Iwasaki T; Murakami M; Sugisaki C; Sobue S; Ohashi H; Asano H; Suzuki M; Nakamura S; Ito M; Murate T
    Pathol Int; 2008 Jun; 58(6):353-60. PubMed ID: 18477214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypochromic red blood cells in low-risk myelodysplastic syndromes: effects of treatment with hemopoietic growth factors.
    Ljung T; Bäck R; Hellström-Lindberg E
    Haematologica; 2004 Dec; 89(12):1446-53. PubMed ID: 15590394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autologous lymphocytes inhibit hemopoiesis in long-term culture in patients with myelodysplastic syndrome.
    Baumann I; Scheid C; Koref MS; Swindell R; Stern P; Testa NG
    Exp Hematol; 2002 Dec; 30(12):1405-11. PubMed ID: 12482502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of cA2 anti-tumor necrosis factor-alpha antibody therapy on hematopoiesis of patients with myelodysplastic syndromes.
    Boula A; Voulgarelis M; Giannouli S; Katrinakis G; Psyllaki M; Pontikoglou C; Markidou F; Eliopoulos GD; Papadaki HA
    Clin Cancer Res; 2006 May; 12(10):3099-108. PubMed ID: 16707608
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD34+ cell selection is required to assess HOXA9 expression levels in patients with myelodysplastic syndrome.
    Heinrichs S; Berman JN; Ortiz TM; Kornblau SM; Neuberg DS; Estey EH; Look AT
    Br J Haematol; 2005 Jul; 130(1):83-6. PubMed ID: 15982348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The clinical significance of activated lymphocytes in patients with myelodysplastic syndromes: a single centre study of 131 patients.
    Meers S; Vandenberghe P; Boogaerts M; Verhoef G; Delforge M
    Leuk Res; 2008 Jul; 32(7):1026-35. PubMed ID: 18006057
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Limited numbers of apoptotic cells in fresh paraffin embedded bone marrow samples of patients with myelodysplastic syndrome.
    Brada SJ; van de Loosdrecht AA; Koudstaal J; de Wolf JT; Vellenga E
    Leuk Res; 2004 Sep; 28(9):921-5. PubMed ID: 15234568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.